Cargando…
Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications
Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the U...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428227/ https://www.ncbi.nlm.nih.gov/pubmed/30906670 http://dx.doi.org/10.1089/biores.2018.0028 |
_version_ | 1783405367695245312 |
---|---|
author | Morita, Yasushi Okura, Hanayuki Matsuyama, Akifumi |
author_facet | Morita, Yasushi Okura, Hanayuki Matsuyama, Akifumi |
author_sort | Morita, Yasushi |
collection | PubMed |
description | Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the United States, 895 in Japan, and 420 in Europe, with 5% of applications for disease-specific cell technologies. In contrast, the percentages of patent applications for iPSC preparation and differentiation technologies were 17% and 23%, respectively. Patent applications for disease-specific cell technologies were classified into four technical fields and 14 disorder groups. In the technical fields, patent applications for genetically engineered cell technologies were prominent, accounting for 63%, 50%, and 65% of the U.S., Japanese, and European applications for 11, 8, and 7 disorder groups, respectively. In the disorder groups, the percentages of patent applications for neurological disorders were 40%, 32%, and 40% of the U.S., Japanese, and European applications, respectively, which were filed in four technical fields in the U.S. and Japanese applications. The U.S. patent applications for disease-specific cell technologies were filed by applicants in the United States, Japan, France, Belgium, Italy, Korea, and Canada; however, patent applications filed by those in Belgium, Italy, and Canada were not found in the Japanese and European applications. The percentages of patent applications filed by the U.S. applicants were 72%, 55%, and 65% of the U.S., Japanese, and European applications, respectively. Most patent applications filed by the U.S. applicants were in the field of genetically engineered cells for 11 disorder groups, which mostly included neurological and blood disorders. Japanese applicants mainly filed patent applications for drug screening technologies; subjects included five disorder groups, particularly neurological and bone/articular disorders. French applicants filed patent applications for neurological disorders in the field of genetically engineered cells and drug screening technologies. Korean applicants filed patent applications for patient-derived cell technologies for neurological, metabolic, and chromosomal/genetic disorders. In conclusion, more than half of patent applications were for genetically engineered cells for 11 disorders, most of which were filed by U.S. applicants. |
format | Online Article Text |
id | pubmed-6428227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-64282272019-03-22 Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications Morita, Yasushi Okura, Hanayuki Matsuyama, Akifumi Biores Open Access Comprehensive Review Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the United States, 895 in Japan, and 420 in Europe, with 5% of applications for disease-specific cell technologies. In contrast, the percentages of patent applications for iPSC preparation and differentiation technologies were 17% and 23%, respectively. Patent applications for disease-specific cell technologies were classified into four technical fields and 14 disorder groups. In the technical fields, patent applications for genetically engineered cell technologies were prominent, accounting for 63%, 50%, and 65% of the U.S., Japanese, and European applications for 11, 8, and 7 disorder groups, respectively. In the disorder groups, the percentages of patent applications for neurological disorders were 40%, 32%, and 40% of the U.S., Japanese, and European applications, respectively, which were filed in four technical fields in the U.S. and Japanese applications. The U.S. patent applications for disease-specific cell technologies were filed by applicants in the United States, Japan, France, Belgium, Italy, Korea, and Canada; however, patent applications filed by those in Belgium, Italy, and Canada were not found in the Japanese and European applications. The percentages of patent applications filed by the U.S. applicants were 72%, 55%, and 65% of the U.S., Japanese, and European applications, respectively. Most patent applications filed by the U.S. applicants were in the field of genetically engineered cells for 11 disorder groups, which mostly included neurological and blood disorders. Japanese applicants mainly filed patent applications for drug screening technologies; subjects included five disorder groups, particularly neurological and bone/articular disorders. French applicants filed patent applications for neurological disorders in the field of genetically engineered cells and drug screening technologies. Korean applicants filed patent applications for patient-derived cell technologies for neurological, metabolic, and chromosomal/genetic disorders. In conclusion, more than half of patent applications were for genetically engineered cells for 11 disorders, most of which were filed by U.S. applicants. Mary Ann Liebert, Inc., publishers 2019-03-19 /pmc/articles/PMC6428227/ /pubmed/30906670 http://dx.doi.org/10.1089/biores.2018.0028 Text en © Yasushi Morita et al. 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Comprehensive Review Morita, Yasushi Okura, Hanayuki Matsuyama, Akifumi Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title | Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title_full | Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title_fullStr | Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title_full_unstemmed | Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title_short | Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications |
title_sort | patent application trends of induced pluripotent stem cell technologies in the united states, japanese, and european applications |
topic | Comprehensive Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428227/ https://www.ncbi.nlm.nih.gov/pubmed/30906670 http://dx.doi.org/10.1089/biores.2018.0028 |
work_keys_str_mv | AT moritayasushi patentapplicationtrendsofinducedpluripotentstemcelltechnologiesintheunitedstatesjapaneseandeuropeanapplications AT okurahanayuki patentapplicationtrendsofinducedpluripotentstemcelltechnologiesintheunitedstatesjapaneseandeuropeanapplications AT matsuyamaakifumi patentapplicationtrendsofinducedpluripotentstemcelltechnologiesintheunitedstatesjapaneseandeuropeanapplications |